Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Sofinnova Ventures Stories

2014-02-10 08:25:15

BURLINGAME, Calif., Feb. 10, 2014 /PRNewswire/ -- First Aid Shot Therapy® (F.A.S.T.), a consumer healthcare company focused on over-the-counter (OTC) medicine in liquid 'shot' (40ml / 1.35oz.) form, announced today that it has completed a Series B financing round. Sofinnova Ventures and Redmile Group co-led the round with additional support from investors including Sofinnova HealthQuest, Clearwell Group and Mark Rampolla, Founder and former CEO of ZICO Beverages, maker of ZICO Pure...

2013-07-24 08:29:09

Reinforces Commitment to Limited Partners and Entrepreneurs MENLO PARK, Calif., July 24, 2013 /PRNewswire/ -- Sofinnova Ventures, a Menlo Park investment firm, today announced the promotion of Jennifer James to Partner. James managed investor relations through the firm's most recent fundraising effort for SVP VIII, a $440M life science focused fund. James' promotion to Partner solidifies Sofinnova's commitment to build best practices in communications and investor relations....

2013-05-21 12:29:11

Consumer Healthcare Company Focused on Over-the-Counter (OTC) Therapies in Liquid 'Shot' Form to Launch First Products in U.S. in Summer 2013 BURLINGAME, Calif., May 21, 2013 /PRNewswire/ -- First Aid Shot Therapy®, Inc. ("F.A.S.T."), a consumer healthcare company focused on over-the-counter (OTC) therapies in liquid 'shot' (40ml / 1.35oz.) form, today announced it has completed a Series A financing round. New investor Sofinnova Ventures led the round. (Logo:...

2013-05-02 08:35:35

Srinivas Akkaraju Joins Sofinnova Ventures as General Partner; Anand Mehra Promoted to General Partner MENLO PARK, Calif., May 2, 2013 /PRNewswire/ -- Sofinnova Ventures, a Menlo Park investment firm, today announced a senior team addition and key promotion. Srinivas Akkaraju, M.D., Ph.D. has joined the firm as General Partner and Anand Mehra, M.D., has been promoted to General Partner. A long-term investor in the life science sector, Dr. Akkaraju will actively invest in...

2013-01-07 08:29:26

BRANFORD, Conn., Jan. 7, 2013 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. Based in Branford, Connecticut, Marinus is the developer of the first-in-class, neuroactive steroid Ganaxolone. Marinus Pharmaceuticals--the leader in the development of...

2013-01-03 08:25:20

SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ -- Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced the completion of a $31 Million Series A financing from four leading venture capital firms, venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a Phase 2 ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P....

2012-12-04 08:27:56

SAINT PETERSBURG, Fla., Dec. 4, 2012 /PRNewswire/ -- Salveo Specialty Pharmacy, Inc., a specialty pharmacy company backed by Three Arch Partners, NewSpring Capital and Petra Capital Partners, today announces the completion of a second round of equity and debt funding, and its subsequent acquisition of Mission Road Pharmacy, a pharmacy based in Los Angeles, California focused on Oncology, HIV/AIDS, Hepatitis, Rheumatoid Arthritis and Mental Health therapies. The additional equity...

2012-10-17 07:25:42

LA JOLLA, Calif., Oct. 17, 2012 /PRNewswire/ -- Cebix Incorporated, a biopharmaceutical company developing treatments for complications of diabetes, today announced results of a Phase 1/2 trial of its lead investigational drug, ERSATTA(TM) in peripheral neuropathy. ERSATTA is the first once-weekly C-peptide therapy to target loss of nerve function and other vascular complications in type 1 diabetes patients. The successful 72 subject trial, which focused on safety, tolerability, and...

2011-07-18 06:00:00

BRISBANE, Calif., July 18, 2011 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners. (Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO ) "We believe that SARcode is uniquely positioned...

2011-03-07 05:00:00

RESEARCH TRIANGLE PARK, N.C., March 7, 2011 /PRNewswire/ -- Aerie Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $30 million Series B financing. Clarus Ventures and Sofinnova Ventures co-led the round, with participation from Osage University Partners, and existing investors Alta Partners and TPG Biotech. Aerie expects to use proceeds from this financing to fund continued...